Literature DB >> 6593071

A novel biologically active seleno-organic compound--III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages.

M J Parnham, S Kindt.   

Abstract

PZ 51 (2-phenyl-1,2-benzisoselenazol-3(2H)-on), a selenium-containing compound with glutathione peroxidase (GSH-Px)-like activity, was administered to selenium-deficient mice for 5 days. A significant increase in peritoneal macrophage GSH-Px activity after treatment was only observed when basal GSH-Px activity was almost zero (i.e. in 19 weeks selenium-deficient animals), possibly due to binding of PZ 51 to the macrophages. This indicates that PZ 51 releases very little, if any, free selenium for incorporation into endogenous GSH-Px. The compound in vitro exerted a concentration-dependent inhibition of the generation of chemiluminescence by resident mouse peritoneal macrophages and a partial inhibition of the production of prostaglandin E2 by resident peritoneal macrophages. beta-Glucuronidase production by C. parvum-activated peritoneal macrophages was unaffected by PZ 51. These in vitro data can be explained on the basis of a selective peroxide scavenging and/or GSH-Px-like activity of PZ 51, offering a novel approach to anti-inflammatory therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6593071     DOI: 10.1016/0006-2952(84)90085-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

Review 1.  The pharmacology of ebselen.

Authors:  M J Parnham; S Leyck; E Graf; E J Dowling; D R Blake
Journal:  Agents Actions       Date:  1991-01

2.  Selective inhibition of leukotriene B4 formation by Ebselen: a novel approach to antiinflammatory therapy.

Authors:  P Kuhl; H O Borbe; A Römer; H Fischer; M J Parnham
Journal:  Agents Actions       Date:  1986-01

3.  Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications.

Authors:  Michael J Parnham
Journal:  Inflamm Res       Date:  2016-09-28       Impact factor: 4.575

4.  Acute antiinflammatory and gastric effects of the seleno-organic compound ebselen.

Authors:  S Leyck; M J Parnham
Journal:  Agents Actions       Date:  1990-06

5.  Proceedings of the British Pharmacological Society. 18th-20th December 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

6.  Susceptibility of methicillin-resistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51).

Authors:  R Nozawa; T Yokota; T Fujimoto
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  Small Molecule Regulators of Ferroptosis.

Authors:  Sylvain Debieu; Stéphanie Solier; Ludovic Colombeau; Antoine Versini; Fabien Sindikubwabo; Alison Forrester; Sebastian Müller; Tatiana Cañeque; Raphaël Rodriguez
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Early investigational drugs for hearing loss.

Authors:  Debashree Mukherjea; Sumana Ghosh; Puspanjali Bhatta; Sandeep Sheth; Srinivasan Tupal; Vikrant Borse; Thomas Brozoski; Kelly E Sheehan; Leonard P Rybak; Vickram Ramkumar
Journal:  Expert Opin Investig Drugs       Date:  2014-09-22       Impact factor: 6.206

9.  Ebselen improves ischemia-reperfusion injury after rat lung transplantation.

Authors:  Jürg Hamacher; Uz Stammberger; Elvira Weber; Rudolf Lucas; Albrecht Wendel
Journal:  Lung       Date:  2009-02-07       Impact factor: 2.584

10.  Antimalarial properties of ebselen.

Authors:  A M Hüther; Y Zhang; A Sauer; M J Parnham
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.